2008
Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow
Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow. Journal Of Nuclear Medicine 2008, 49: 517-523. PMID: 18344436, DOI: 10.2967/jnumed.107.048504.Peer-Reviewed Original ResearchConceptsBlood flowUptake scanPET scansControl ROIMore tumor sitesFirst-pass uptakeTumor blood flowEarly uptakeRegional blood flowNovel antiangiogenic agentsArterial blood concentrationDose-escalating protocolPET molecular imagingMeasured blood flowPerfusion scanEstimate of perfusionBlood concentrationsBolus injectionProstate cancerAntiangiogenic agentsTumor perfusionGlucose metabolismBlood flow analysisBack musclesLarge arteries
2000
9:00—9:15 Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors
Mullani N, Herbst R, Abbruzzese J, Charnsangavej C, Kim E, Tran H, Barron B, Lamki L, Gould K. 9:00—9:15 Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors. Molecular Imaging And Biology 2000, 3: 151. PMID: 11150754, DOI: 10.1016/s1095-0397(00)00063-7.Peer-Reviewed Original ResearchStandard uptake valueTumor blood flowBlood flowGlucose metabolismImaged tumorsTumor-bearing sitesStart of therapyTumor metabolic activityRegional blood flowNovel antiangiogenic agentsDays of treatmentNon-invasive imagingAntiangiogenic treatmentAntiangiogenic agentsPatientsDose levelsUptake valueTumorsHuman tumorsPercentage changePhase IOxygen-15Flourine-18TreatmentDose